For Women FDA-approved treatment for HSDD: Clinical studies demonstrated that PT-141 significantly increased sexual desire scores in women diagnosed with hypoactive sexual desire disorder
Tirzepatide, sold as Mounjaro and Zepbound, combines GLP-1 and GIP
FIGURE 5 4 Discussion DM is a major health concern and a leading cause of CKD worldwide, resulting in substantial impairments in the quality of life, a higher incidence of premature mortality, increased risk of major cardiovascular events, and a significant burden on health-care systems (Francis et al., 2024)
Caroline Apovian, codirector of the Center for Weight Management and Wellness at Brigham and Womens Hospital in Boston, says that because compounded drugs are not reviewed for safety, quality, and effectiveness, there is potential for variation across compounded medications